Discontinuing HER2-Directed Therapy for Metastatic Breast Cancer
This study is looking at whether people with HER2-positive metastatic (Stage IV) breast cancer who are in complete remission can stop their anti-HER-2 maintenance treatments, such as Herceptin. The main goal is to see if patients can stay in remission after stopping these treatments and for how long. You might be able to join if you have HER2-positive metastatic breast cancer and your scans show you are in complete remission. The study aims to enroll 20 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific intervention. It plans to enroll 20 participants.
- What's involved
- Patients assigned to the intervention group will be asked to discontinue anti-HER-2 maintenance treatment. Monitoring will include radiologic imaging and routine blood work.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure how long patients stay in remission for up to 72 months after discontinuing treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Elisa Krill Jackson, MD · PRINCIPAL_INVESTIGATOR · University of Miami
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Feasibility of maintaining remission after discontinuing use of anti-HER-2Up to 72 months
The feasibility of maintaining remission of HER-2 will be measured as the proportion of patients who discontinue anti-HER-2 therapy and who remain in remission is assessed by monitoring ctDNA in the blood.